915 related articles for article (PubMed ID: 26121196)
1. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.
Teng MW; Bowman EP; McElwee JJ; Smyth MJ; Casanova JL; Cooper AM; Cua DJ
Nat Med; 2015 Jul; 21(7):719-29. PubMed ID: 26121196
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.
Johnsson HJ; McInnes IB
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S115-8. PubMed ID: 26471946
[TBL] [Abstract][Full Text] [Related]
3. New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers.
Chyuan IT; Lai JH
Biochem Pharmacol; 2020 May; 175():113928. PubMed ID: 32217101
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease.
Aggeletopoulou I; Assimakopoulos SF; Konstantakis C; Triantos C
World J Gastroenterol; 2018 Sep; 24(36):4093-4103. PubMed ID: 30271076
[TBL] [Abstract][Full Text] [Related]
5. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade.
Schurich A; Raine C; Morris V; Ciurtin C
Rheumatology (Oxford); 2018 Feb; 57(2):246-254. PubMed ID: 28541488
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
Deepak P; Loftus EV
Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
[TBL] [Abstract][Full Text] [Related]
7. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M; Alwawi E; Gordon KB
Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-23: a key cytokine in inflammatory diseases.
Duvallet E; Semerano L; Assier E; Falgarone G; Boissier MC
Ann Med; 2011 Nov; 43(7):503-11. PubMed ID: 21585245
[TBL] [Abstract][Full Text] [Related]
9. IL-12 protects from psoriasiform skin inflammation.
Kulig P; Musiol S; Freiberger SN; Schreiner B; Gyülveszi G; Russo G; Pantelyushin S; Kishihara K; Alessandrini F; Kündig T; Sallusto F; Hofbauer GF; Haak S; Becher B
Nat Commun; 2016 Nov; 7():13466. PubMed ID: 27892456
[TBL] [Abstract][Full Text] [Related]
10. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.
Benson JM; Sachs CW; Treacy G; Zhou H; Pendley CE; Brodmerkel CM; Shankar G; Mascelli MA
Nat Biotechnol; 2011 Jul; 29(7):615-24. PubMed ID: 21747388
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab.
Luo J; Wu SJ; Lacy ER; Orlovsky Y; Baker A; Teplyakov A; Obmolova G; Heavner GA; Richter HT; Benson J
J Mol Biol; 2010 Oct; 402(5):797-812. PubMed ID: 20691190
[TBL] [Abstract][Full Text] [Related]
13. Treatment of psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
[TBL] [Abstract][Full Text] [Related]
15. Update on ustekinumab for the treatment of Crohn's disease.
Leung Y; Panaccione R
Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262
[TBL] [Abstract][Full Text] [Related]
16. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
Mease PJ
Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
[TBL] [Abstract][Full Text] [Related]
18. IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy.
Furfaro F; Gilardi D; Allocca M; Cicerone C; Correale C; Fiorino G; Danese S
Expert Rev Clin Immunol; 2017 May; 13(5):457-467. PubMed ID: 28067059
[TBL] [Abstract][Full Text] [Related]
19. IL-23 orchestrating immune cell activation in arthritis.
Najm A; McInnes IB
Rheumatology (Oxford); 2021 Oct; 60(Suppl 4):iv4-iv15. PubMed ID: 34668017
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.
Frieder J; Kivelevitch D; Haugh I; Watson I; Menter A
Clin Pharmacol Ther; 2018 Jan; 103(1):88-101. PubMed ID: 28960267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
